biotech Portuguese pharmaceutical group Bluepharma consists of ten companies that represent different parts of the medicine value chain. The success of Bluepharma during Portugal’s crisis was due to a strong focus on overseas exports and diversification of risk. Paulo Barradas and Sérgio Simões explain how they created that success. Bluepharma…
R&D Nuno Arantes-Oliveira, President of P-BIO, Portugal’s Biotechnology Industry Organization, the country’s sole association for biotechnology companies, discusses the state of the biotech industry today in Portugal, and the ways in which the industry can consolidate and attract overseas investment to stimulate growth. After a harsh economic downturn over the…
Biotechnology Despite Portugal’s economic woes, some local companies have been able to adjust accordingly and succeed in this environment. Tecnifar is no exception. The company’s CEO, António Chaves Costa, talks about Tecnifar’s in-licensing strategy, as well as its diversification of investments and future plans for export business. Last year, Tecnifar…
CEO Talk In the second part of this two-part interview, the chairman of TTY looks back at his experiences in the Taiwanese market, and assess what could have been done differently with his company. He also offers advice to the next generation of Taiwanese pharmaceutical companies. To read the first part of…
Biogenerics The founder and general manager of Biotechnova considers the potential of Colombia for biotechnological innovation, and explains the current state of the biogeneric industry in Latin America. Please start by introducing yourself, and explaining how you came to found Biotechnova. My background is in microbiology and infections: since 2003, there…
Biotechnology Pedro Ferraz da Costa, CMO Iberfar’s president, discusses generic competition in Portugal, his company’s expansion into Angola and southern Africa, and the company’s competitive advantages with its various subsidiaries. There is some debate whether or not the Portuguese market is a predictable market. From your experience, what is the market’s…
Array In Taiwan, biotech is finally booming, and more and more of the companies benefitting from this boom are listing on the Gre Tai Securities Market (GTSM), built with small to medium enterprises in mind, and tailored for companies that are part of emerging industries. But are these companies overvalued, and…
Array The past three years have been some of the most eventful in memory for Taiwan’s life sciences industry. At this year’s Bio Taiwan exhibition, the annual conference that invites the international life sciences com-munity to the island, the excitement was palpable. Foreign companies turned out in record numbers to…
BIOQuébec Mr. Lebrun discusses the role that BIOQuébec plays in the industry, its aims in representing several sectors and their plans for the coming years. Could you introduce BIOQuébec and its main priorities to our readers? BIOQuébec is a voluntary trade association representing Québec-based life sciences organizations. Its membership includes biotechnology…
Botanical drugs The Chairman and CSO of TCM Biotech offer perspectives on the potential of botanical drugs, and chart their biotech company’s trajectory in bringing these drugs to both the Chinese and US markets. Mr. Hsu, can you please introduce our readers to yourself and to TCM Biotech? Shining Hsu (SH): I…
Newbridge Pharmaceuticals Joe Henein, President & CEO of Newbridge Pharmaceuticals, talks about the evolution of the company since his joining, what makes Newbridge Pharmaceuticals a unique partner within the industry, and expounds on the many possible options for the future of the company. Newbridge Pharmaceuticals is a unique company within the Middle…
See our Cookie Privacy Policy Here
